Prandial insulin regimen is associated with lower patient satisfaction in T2DM patients
December - 1 - 2011
Many type 2 diabetes (T2DM) patients need insulin therapy for glycemic control, with a significant impact on quality of life (QoL) and treatment satisfaction. The treat-to-target in T2DM (4-T) trial was a randomized, open-label study of T2DM patients which compared biphasic, prandial or basal insulin regimen as add-on to oral antidiabetes therapy. The EuroQol-5-Dimension questionnaire used in the study did not find any significant differences in patient health status. Additional analysis compared scores in Insulin Treatment Satisfaction Questionnaires (ITSQ) in 708 T2DM subjects. At 1 year, 78.2% of patients completed all 22 items of ITSQ and 88.4% completed at least 1 item. All scores were adjusted for confounding demographic factors. Mean total ITSQ score as well as subscores in all domains were lower in the prandial group than in the other two insulin regimens. Increase in body mass index and hypoglycemia episodes were also associated with lower ITSQ scores (thus lower treatment satisfaction). Scores in self-completed ITSQ at 1 year were able to detect differences in patient satisfaction between 3 different insulin regimens. The results indicate a need for identifying optimal insulin treatment regimen in this patient population (Farmer, A.J. et al. Diabetes Obes Metab 2011, 13(12): 1136).